pharmaphorum

JUNE 23, 2022

Novartis has shouldered its way into the in vivo gene editing category via a deal with US biotech Precision BioSciences, focused on a therapy for sickle cell disease (SCD). billion in potential milestones if the project advances through development and onto the market. billion agreement that started in 2020.

Gene Editing 97

Gene Editing In-Vivo Gene Sequencing Gene 97

Drug Discovery World

MARCH 4, 2024

DDW Editor Reece Armstrong speaks to Abraham Wang , Head of Marketing at Collaborative Drug Discovery (CDD) about annotated assays and the advantages they bring to research teams. RA: What advantages can better analysis into assays bring to drug developers?

Drugs 59

Drugs Bioassay Scientist In-Vivo 59

Drug Discovery World

AUGUST 14, 2023

While CGT is still an emerging market, its growth has accelerated over the last five years, resulting in a wave of products approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Driven by the rapid pace of innovation, the market for CGTs is expected to grow from $4.4

Gene Therapy 52

Gene Therapy Marketing Gene DNA 52

pharmaphorum

FEBRUARY 13, 2022

German drugmaker Merck KGaA has reached an agreement to pilot an artificial intelligence platform developed by Quris that aims to identify potential safety problems with new therapeutic candidates as early as possible in the drug discovery process.

Drugs 98

Drugs In-Vivo In-Vitro Pharma Companies 98

Drug Discovery World

APRIL 10, 2023

Could India become an important centre of drug discovery innovation? Thanks to a new focus on R&D, increasing digitalisation and government investment, India is establishing itself as a significant player in drug discovery, and the Hyderabad life sciences hub has played a significant role in this.

Genome 52

Genome Genomics Drugs Life Science 52

The Pharma Data

JANUARY 17, 2021

But that number doesn’t quite reflect the company’s likely market valuation , which is expected to be between $9 billion and $12 billion. Based in Seattle, Washington, Sana focuses on in vivo and ex vivo cell engineering platforms to develop therapies for cancer, diabetes, cardiovascular disease, CNS disorders, and genetic diseases.

In-Vivo 52

In-Vivo Marketing Engineer Genetics 52

Drug Discovery World

AUGUST 3, 2023

The transaction expands Sygnature’s business operations into the North American market. NuChem Sciences employs over 300 staff in Montreal and Quebec City, Canada, where the company will continue to operate and drive further market expansion across North America.

In-Vivo 52

In-Vivo In-Vitro Protein Marketing 52

Drug Discovery World

JANUARY 18, 2024

Poolbeg Pharma, a biopharmaceutical company focused on the development and commercialisation of medicines targeting diseases with a high unmet medical need, has announced promising in vivo results for POLB 001 in addressing cancer immunotherapy-induced cytokine release syndrome (CRS). million cases of cancer by 2030 1,2.

In-Vivo 64

In-Vivo Antibody Clinical Trials Clinical Trials 64

pharmaphorum

APRIL 12, 2021

Sanofi has licensed a potential inflammatory diseases drug from Manchester University spin-off C4X Discovery Holdings in a deal worth up to €414 million ($492 million). While the headline figure looks significant the UK biotech will receive only €7 million up front, reflecting the fact that the drug has not yet begun clinical testing.

Drugs 52

Drugs In-Vivo Licensing Licensing 52

Drug Discovery World

APRIL 15, 2024

DDW’s Megan Thomas speaks to experts from the drug discovery industry about their predictions on the future of stem cells in drug discovery. Gene therapy will move to ex vivo gene modification and the delivery of gene-modified cell types. In addition, I believe we will see more exosome-based therapies enter the clinic in 2024.

Gene Editing 59

Gene Editing Clinical Trials Clinical Trials In-Vivo 59

Drug Discovery World

MAY 26, 2023

There are currently no treatments on the market that effectively reverse scarring. AM1476 has been found to ameliorate key fibrotic pathways in vivo and ex vivo with the potential to halt and reverse scarring with potential utility across fibrotic disease.

In-Vivo 52

In-Vivo Trials Marketing Drugs 52

Camargo

DECEMBER 22, 2021

Informed by today’s competitive drug development landscape, as well as by the sponsor’s strategic goals and capabilities, a portfolio analysis involves assessing product concept and differentiation, strategic planning, factoring in unmet patient needs, and estimating timelines and expenses. Incentive Programs. Clinical Pharmacology.

Bioequivalency 169

Bioequivalency Production Genotoxicity In-Vivo 169

Drug Discovery World

APRIL 4, 2023

The Food and Drug Administration (FDA) in the US has made several key drug decisions over the last few weeks. The drug was granted orphan drug designation by the FDA in May 2021. The designation is the first step to gaining a priority review voucher (PRV), which can accelerate market access for therapeutics.

FDA Approval 52

FDA Approval In-Vivo Gene Editing Drugs 52

pharmaphorum

JUNE 12, 2022

A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has continued to show impressive results in clinical trial, with an update at the EHA congress showing long-term effects on the symptoms of both beta thalassaemia and sickle cell disease. billion product if it gets approved for both indications.

Gene Editing 59

Gene Editing Gene Gene Therapy Drugs 59

Camargo

NOVEMBER 11, 2020

When the FDA requires a product’s labeling to include a boxed warning (also called a “black box warning” because the text is surrounded by black border), the potential market value of the drug often drops severely. Presumably, Antares’ long-established 90-person urology sales force can achieve pull-thru of this drug product.

Development 242

Development Bioequivalency Generic Drugs Production 242

pharmaphorum

APRIL 23, 2021

The alliance is based on Obsidian’s cytoDRIVE platform, which uses already approved small-molecule drugs alongside gene-editing medicines to control the expression of protein from a gene sequence. Alternatively, a drug can be administered that switches off the genetic medicine and brings protein expression to a halt.

Gene Editing 52

Gene Editing Genetics Drugs Gene 52

The Pharma Data

NOVEMBER 24, 2020

The acquisition, which is expected to close in January 2021, will expand Selvita’s integrated drug discovery services and will check off one of the company’s 2020 to 2023 goals it announced in April. Fidelta’s Managing Director, Adrijana Vinter, suggests the acquisition will strengthen Fidelta’s presence on the market.

Drugs 52

Drugs In-Vivo Marketing Development 52

Roots Analysis

FEBRUARY 15, 2023

A study conducted on terminated drug development projects revealed that majority of the drug candidates fail in early drug development phases, due to the problems associated with their pharmacokinetic profiles, ADME ( distribution, metabolism, absorption and excretion ) properties and toxicity-related issues.

Bioavailability 52

Bioavailability In-Vivo Marketing Drugs 52

pharmaphorum

JANUARY 29, 2021

Since that discovery, a flurry of gene-editing focused biopharma companies have launched – including Intellia Therapeutics, CRISPR Therapeutics, Caribou Biosciences and Mammoth Biosciences – and the first drug therapies based on the technology are now in human testing for diseases like cancer. Zinc fingers. billion in funding.

Gene Editing 145

Gene Editing Gene Gene Therapy In-Vivo 145

Drug Discovery World

FEBRUARY 15, 2024

The etherna paradigm for cLNP design is ushering in the rapid generation of novel families of delivery systems for not only vaccination but also for in vivo tolerisation for a host of autoimmune diseases.” The post LNP formulations produce strong immune responses, data shows appeared first on Drug Discovery World (DDW).

Immune Response 52

Immune Response In-Vivo Vaccination Vaccine 52

pharmaphorum

SEPTEMBER 28, 2022

Vertex Pharma and partner CRISPR Therapeutics will start a rolling marketing application in the US for their gene-editing drug for sickle cell disease (SCD) and beta thalassaemia later this year. The time places exa-cel in pole position to become the first drug developed based on CRISPR/Cas9 gene-editing technology to reach the market.

Gene Editing 59

Gene Editing Gene In-Vivo Clinical Trials 59

Drug Discovery World

APRIL 25, 2023

Drug-induced mitochondrial dysfunction has been linked to compound attrition, organ toxicity, black-box warnings, and market withdrawals. Understand the importance of testing in early-phase drug discovery. Learn about new in vitro methods that can easily be incorporated into your drug safety workflow.

In-Vitro 52

In-Vitro Drugs Marketing In-Vivo 52

Drug Discovery World

APRIL 25, 2023

Drug-induced mitochondrial dysfunction has been linked to compound attrition, organ toxicity, black-box warnings, and market withdrawals. Understand the importance of testing in early-phase drug discovery. Learn about new in vitro methods that can easily be incorporated into your drug safety workflow. Download now.

In-Vitro 52

In-Vitro Drugs Marketing In-Vivo 52

Pharmaceutical Technology

MARCH 9, 2023

Innovation S-curve for the pharmaceutical industry Transgenic murine models is a key innovation area in pharmaceutical s Transgenic murine models refer to mice that have been genetically altered for the purposes of understanding the in vivo functions of genes. Regeneron Pharmaceuticals is the leading patent filer in transgenic murine models.

In-Vivo 130

In-Vivo Antibody Genetics Gene 130

Drug Discovery World

AUGUST 22, 2023

In September 2021, the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) announced the initiation of a pilot programme 1 to provide parallel scientific advice to pharma companies applying for marketing authorisation for generic versions of hybrid products and complex generic drug products.

Production 52

Production Bioequivalency In-Vivo In-Vitro 52

The Pharma Data

DECEMBER 9, 2020

Artificial intelligence holds immense promise to catalyze the development of the next generation of highly selective, orally bioavailable molecules, with reduced side effects, for the most impactful drug targets,” Feinberg said at the time of the launch. which will remain a key shareholder. SciNeuro Pharmaceuticals. in a statement. .

Marketing 52

Marketing In-Vivo Protein In-Vitro 52

The Pharma Data

JUNE 7, 2023

Acuitas’ LNP technology will support Bayer’s in vivo gene editing and protein replacement programs by specifically delivering RNA payloads to the desired target organ, the liver. LNPs are spheric drug delivery bodies which can be equipped with therapeutic payloads for intracellular delivery. Source link: [link]

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

Drug Discovery World

FEBRUARY 6, 2023

MT: Can you provide me with an overview of what Infinimmune does currently and the potential it sees in the antibody-based therapeutics market? WM : Infinimmune is an early-stage antibody biotechnology company, focused on reinventing antibody drug discovery by developing human-derived antibody drugs.

Antibody 52

Antibody Immune Response Genome Genomics 52

Drug Discovery World

MARCH 12, 2024

To this end, a grant of $3 million offered in the Bio Studio programme to mature a technology for ‘platform-market-fit’ is a unique opportunity for translational projects. RA: Biomia is developing drug candidates for pain, addiction and mental health conditions. What are some of the historical challenges with these drugs?

Medicine 59

Medicine Production Drugs In-Vivo 59

Drug Discovery World

NOVEMBER 16, 2022

In April 2021, life sciences solutions provider Molecular Devices launched its Organoid Innovation Centre (OIC), an initiative designed to help scientists leverage the potential of 3D biology throughout the drug discovery process. . 2D vs 3D . 2D biology has been used by pharmaceutical researchers for decades. 2D vs 3D .

Drugs 97

Drugs In-Vivo In-Vitro Scientist 97

XTalks

DECEMBER 13, 2023

The US Food and Drug Administration (FDA) has approved the first gene therapies for the treatment of sickle cell disease, approving two on the same day. The landmark approvals were awarded to bluebird bio’s Lyfgenia (lovo-cel) and Vertex Pharmaceuticals and CRISPR Therapeutics’ jointly developed Casgevy (exa-cel).

Gene Therapy 98

Gene Therapy FDA Approval Gene In-Vivo 98

Roots Analysis

SEPTEMBER 5, 2023

The early stages of research related to drug discovery, including the identification of a relevant biological target and a viable lead compound, play a crucial role in the overall success of a drug candidate in preclinical and clinical studies. Traditional methods used for drug discovery are time-consuming and resource intensive.

Drugs 52

Drugs In-Vivo Development Research 52

Drug Discovery World

SEPTEMBER 28, 2022

Ben Folwell, Principal Consultant at Citeline, maps out how AI, swarm learning and open access to clinical data could revolutionise drug discovery. . Its application in pharma, most commonly in drug discovery, has been steadily growing with global partnerships between tech vendors and pharma companies becoming more commonplace.

Pharma Companies 52

Pharma Companies Drugs In-Vivo Genetics 52

The Pharma Data

MARCH 8, 2021

Of 202 treated participants, no safety signals have been identified and of the 4 serious adverse events reported, none were considered to be study drug related. This program included assays such as Big Blue and PIG-a designed to provide a robust measure of a drug or chemical’s ability to induce mutations in vivo.

Trials 69

Trials In-Vivo Genotoxicity RNA 69

Roots Analysis

JANUARY 14, 2024

With the increased interest and gradual shift of investment from small molecule drugs to biologics and the establishment of several biologics manufacturing companies / biologics CMOs, more than 250 biologic therapies and vaccines have been developed, globally. Like all drugs, biologics are regulated by the FDA.

Contract Manufacturing 40

Contract Manufacturing Manufacturing Protein Bacteria 40

Drug Discovery World

JULY 5, 2023

Global Cancer Segment Market Manager at Agilent Technologies, recently sat down with DDW Editor Reece Armstrong to tell us about the developments in the ‘golden age’ of cancer research. Mark Garner, PhD., RA: Please can you tell us a bit more about your role at Agilent? MG: I am responsible for Agilent’s cancer segment.

Research 98

Research Protein Scientist Immune Response 98

The Pharma Data

MARCH 29, 2022

AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination, has been granted marketing authorisation in the European Union (EU) for the pre-exposure prophylaxis (prevention) of COVID-19 in a broad population of adults and adolescents aged 12 years and older weighing at least 40 kg. Christoph D.

Antibody 52

Antibody In-Vivo Vaccination Vaccine 52